All In Biotech

Drug Trial Radar · NCT05139810

OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

A Phase 3 Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ISIS 721744 in Patients With Hereditary Angioedema (HAE)

Last checked: Nov 20, 2026Latest source record: Mar 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

91

Actual

Start

Dec 3, 2021

Primary completion

Nov 9, 2023

Study completion Nov 9, 2023

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
Dec 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the safety and efficacy of donidalorsen in participants with HAE and effect of donidalorsen on the quality and pattern of HAE attacks and their impact on quality of life (QoL).

Conditions

  • Hereditary Angioedema

Interventions

  • DonidalorsenDrug

    Donidalorsen was administered by SC injection.

  • PlaceboDrug

    Donidalorsen-matching placebo was administered by SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time-Normalized Investigator-Confirmed (IC) HAE Attack Rate (Per Month) From Week 1 to Week 25Time frame: Week 1 to Week 25

Locations

51 sites in 14 countries. Site status is shown where the registry gives one.

  • Ionis Investigative Site

    Scottsdale, Arizona

  • Ionis Investigative Site

    San Diego, California

  • Ionis Investigative Site

    Santa Monica, California

  • Ionis Investigative Site

    Walnut Creek, California

  • Ionis Investigative Site

    Colorado Springs, Colorado

  • Ionis Investigative Site

    Tampa, Florida

  • Ionis Investigative Site

    Kansas City, Kansas

  • Ionis Investigative Site

    Boston, Massachusetts

  • Ionis Investigative Site

    Ann Arbor, Michigan

  • Ionis Investigative Site

    St Louis, Missouri

  • Ionis Investigative Site

    Columbus, Ohio

  • Ionis Investigative Site

    Toledo, Ohio

  • Ionis Investigative Site

    Hershey, Pennsylvania

  • Ionis Investigative Site

    Dallas, Texas

  • Ionis Investigative Site

    Murray, Utah

  • Ionis Investigative Site

    Brussels, Belgium

  • Ionis Investigative Site

    Brussels, Belgium

  • Ionis Investigative Site

    Edegem, Belgium

  • Ionis Investigative Site

    Sofia, Bulgaria

  • Ionis Investigative Site

    Sofia, Bulgaria

  • Ionis Investigative Site

    Edmonton, Canada

  • Ionis Investigative Site

    Ottawa, Ontario, Canada

  • Ionis Investigative Site

    Odense, Denmark

  • Ionis Investigative Site

    La Tronche, France

  • Ionis Investigative Site

    Marseille, France

  • Ionis Investigative Site

    Paris, France

  • Ionis Investigative Site

    Berlin, Germany

  • Ionis Investigative Site

    Frankfurt, Germany

  • Ionis Investigative Site

    Munich, Germany

  • Ionis Investigative Site

    Ashkelon, Israel

  • Ionis Investigative Site

    Haifa, Israel

  • Ionis Investigative Site

    Tel Aviv, Israel

  • Ionis Investigative Site

    Catania, Italy

  • Ionis Investigative Site

    Milan, Italy

  • Ionis Investigative Site

    Naples, Italy

  • Ionis Investigative Site

    Padova, Italy

  • Ionis Investigative Site

    Palermo, Italy

  • Ionis Investigative Site

    Amsterdam, Netherlands

  • Ionis Investigative Site

    Groningen, Netherlands

  • Ionis Investigative Site

    Krakow, Poland

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.